N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-(4-(trifluoromethyl)phenyl)-1,4,5,6-tetrahydropyridine-3-carboxamide
規(guī)格:
數(shù)量:
價格:
折后價:
金牌價格:
聯(lián)系客服:
產(chǎn)品描述 | GSK429286A是一種選擇性的ROCK1和ROCK2抑制劑,IC50分別為14 nM和63 nM。 | |||||
---|---|---|---|---|---|---|
靶點 | ROCK1 | ROCK2 | ||||
IC50 | 14 nM?[1] | 63 nM?[2] | ||||
體外研究 | GSK429286A slightly inhibits RSK and p70S6K with IC50 of 0.78 μM and 1.94 μM, respectively. GSK429286A significantly inhibits rat aortic ring dilation with IC50 of 190 nM.?[1]?GSK429286A at 1 μM reduces ROCK2 activity over 20-fold, under conditions in which the only other kinase tested that is significantly inhibited is MSK1 whose activity is reduced ~5-fold. GSK429286A is a more selective ROCK2 inhibitor than the widely utilized ROCK inhibitor Y-27632 as assessed on kinase-specificity panel, and does not significantly inhibit LRRK2 even at doses as high as 30 μM (500-fold higher than IC50 of inhibition of ROCK2). Like GSK269962A but not sunitinib, GSK429286A treatment at 10 μM ablates basal or G14V-Rho mutant induced phosphorylation of MYPT at Thr850 in HEK-293 cells to a similar extent as H-1152 and Y-27632, consistent with ROCK mediating this phosphorylation, whereas GSK429286A does not inhibit ERM protein phosphorylation either in the presence or absence of G14V-Rho.?[2] | |||||
體內(nèi)研究 | GSK429286A has 61% oral bioavailability in male Sprague-Dawley rats. Oral administration of GSK429286A at single doses of 3-30 mg/kg dramatically reduces mean arterial pressure in the spontaneously hypertensive rats (SHRs) in a dose-dependent manner, with a maximum decrease of 50 mmHg after approximately 2 hours treatment at dose of 30 mg/kg.?[1] | |||||
特征 | More selective than Y-27632. |
GSK429286A/864082-47-3 卷曲蛋白激酶(ROCK)抑制劑,50mg化學(xué)屬性
溶解性 (25°C)?* | 體外 | DMSO | 87 mg/mL (201 mM) |
---|---|---|---|
水 | <1 mg/mL (<1 mM) | ||
乙醇 | 4 mg/mL (9 mM) | ||
體內(nèi) | 15% Captisol/citrate vehicle, | 15 mg/mL | |
*?<1 mg/ml 指產(chǎn)品微溶或不溶 *?溶解度檢測是由Selleck技術(shù)部門檢測的,可能會和文獻中提供的溶解度有所差異,這是由于生產(chǎn)工藝和批次不同產(chǎn)生的正?,F(xiàn)象。 |
Chemical Name | N-(6-fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-(4-(trifluoromethyl)phenyl)-1,4,5,6-tetrahydropyridine-3-carboxamide |
---|
其他相關(guān)的 ROCK 產(chǎn)品:
LEE011
LEE011 是一口服有效的,高度特異性CDK4/6抑制劑。
EHop-016
EHop-016 是一種特異性的Rac GTPase抑制劑,作用于Rac1, IC50為1.1 μM,同等有效抑制Rac3。
ZCL278
ZCL278是一個選擇性的Cdc42 GTP酶抑制劑,Kd為11.4 μM。
Y-27632 2HCl
Y-27632 2HCl是一種選擇性的ROCK1(p160ROCK)抑制劑,Ki為140 nM,比對其他激酶包括PKC,cAMP依賴性蛋白激酶, MLCK和PAK的作用強200多倍。
Thiazovivin
Thiazovivin是一種新型ROCK抑制劑,IC50為0.5 μM,在單細胞分離后,促進人胚胎干細胞(hESC)的存活。
Fasudil (HA-1077) HCl
Fasudil (HA-1077) HCl是一種有效的ROCK-II, PKA, PKG, PKC,和MLCK抑制劑, Ki分別為0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM,和36 μM。
RKI-1447
RKI-1447是一種有效的ROCK1和ROCK2抑制劑,IC50分別為14.5 nM和6.2 nM,有抗侵入和抗腫瘤活性。
Palbociclib (PD-0332991) HCl
Palbociclib (PD-0332991) HCl是一種高度選擇性的CDK4/6抑制劑,IC50為11 nM/16 nM,對CDK1/2/5, EGFR, FGFR, PDGFR, InsR等沒有抑制活性。Phase 3。
特征: PD-0332991作為有應(yīng)用前景的工具測定CDK激酶是否具有明顯的治療價值。
Alisertib (MLN8237)
Alisertib (MLN8237)是一種選擇性的Aurora A抑制劑,IC50為1.2 nM,作用于Aurora A比作用于Aurora B選擇性強200倍以上。Phase 3。
特征: MLN8237 是第一個口服有效的小分子Aurora A激酶選擇性抑制劑。
BI 2536
BI 2536是一種有效的Plk1抑制劑,IC50為0.83 nM,比作用于Plk2和Plk3選擇性分別高4和11倍。Phase 2。
特征: BI 2536是第一個有效的Plk1選擇性抑制劑,抑制 Plk1的標記。
OriGen CP-70 CryoPur-DMSO 細胞凍存液 二甲基亞砜 進口USP級 CE認證 CP70
¥1Lifeline LL-0002 VascuLife EnGS Complete Kit 人內(nèi)皮細胞培養(yǎng)基套裝
¥1Anti-Human CD4 PerCP-Cyanine5.5 人CD4抗體
¥4,188Corning 88-571-kit Natural Killer Cell Serum-free Culture Kit II NK細胞活化擴增培養(yǎng)基套裝
¥0Cellartis Y50200 MSC Xeno-Free Culture Medium 人間充質(zhì)干細胞培養(yǎng)基,無外源無需包被
¥1Origen CS250 Freezing Bags vol-max 30-70mL 凍存袋 細胞治療用藥包材
¥1【臍帶血干細胞新藥獲批】CryoStore? 25為干細胞治療保駕護航
首款干細胞治療藥品已上市!OriGen凍存袋助力MSC藥物研發(fā)
ProteanFect:小鼠原代T細胞從提取到轉(zhuǎn)染全流程攻略
貼壁細胞轉(zhuǎn)染優(yōu)選:ProteanFect轉(zhuǎn)染試劑盒 現(xiàn)貨代理
ProteanFect和Lipo系列轉(zhuǎn)染試劑的區(qū)別,怎么選擇?
人原代T細胞轉(zhuǎn)染好選擇:ProteanFect轉(zhuǎn)染試劑盒
ProteanFect CRISPR Cas9轉(zhuǎn)染轉(zhuǎn)染試劑盒 高效遞送
原代免疫細胞轉(zhuǎn)染克星:ProteanFect轉(zhuǎn)染原理介紹
?【買試劑,找華雅】mRNA轉(zhuǎn)染IVT攻略:流程及試劑推薦
CD34+造血干細胞轉(zhuǎn)染神器:ProteanFect Max